That was fast: 3 months after uncloaking, Zentalis guns for IPO
Just before Christmas, Zentalis Pharmaceuticals announced itself formally to the world as a midstage cancer biotech, but with some quiet funding rounds under its belt.
Just before Christmas, Zentalis Pharmaceuticals announced itself formally to the world as a midstage cancer biotech, but with some quiet funding rounds under its belt.
Numab Therapeutics has raised CHF 22 million ($23.8 million) ahead of the start of clinical testing of its lead oncology drug ND021. Daniel Vasella, the former CEO of Novartis, was among the people to participate in the financing round.
First Direct Use Of CRISPR In Humans By Harvard Doctors
Biofuel From Bacteria – Scientists’ New Study Could Boost Biofuel Sector
Rs. 3.6 crore Research grant for pigmentary disorders
The FDA has accepted Urovant Sciences’ filing for approval of overactive bladder prospect vibegron, teeing the biotech up to find out whether it has won approval in the final few days of 2020.
Novartis has entered into a four-year research collaboration with Orionis Biosciences. The agreement tasks Orionis with applying its technologies to “historically elusive targets” in multiple therapeutic areas.
Just a month after getting its Biologics License Application accepted by the FDA for its next-gen breast cancer hopeful, MacroGenics’ senior vice president of clinical development and chief medical officer Jon Wigginton, M.D., is set to leave the company later this month.
PsiOxus Therapeutics has hired Tom Lillie away from Merck to work as its chief medical officer. Lillie’s arrival coincides with the initiation of a phase 1 trial of PsiOxus’ quadrivalent viral gene therapy vector.
AMAG Pharmaceuticals is losing its CEO, likely having a drug pulled off the market by the FDA and has cut more than 100 staffers; as it turns more deeply to its pipeline, the person in charge of that is now leaving.